Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Aurora Spine Corp
Castellum, Inc. Common Stock
Clearmind Medicine Inc
Minehub Technologies Inc
PDF Solutions, Inc. - Common Stock
Porter & Company Property & Casualty Index ETF
SMX (Security Matters) Public Limited Company - Ordinary Shares
Spectral Capital Corp
Spruce Power Holding Corporation Class A Common Stock
Talphera, Inc. - Common Stock
Worldline Sa Ord
Xos, Inc. - Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cellectar Biosciences, Inc. - Common Stock
(NQ:
CLRB
)
1.230
+0.040 (+3.36%)
Delayed Quote
Updated: 1:16 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectar Biosciences, Inc. - Common Stock
< Previous
1
2
Next >
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
October 15, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
September 29, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
July 30, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
July 15, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
June 01, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 14, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
May 11, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
May 05, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
May 05, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
April 21, 2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
April 14, 2026
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
March 04, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
February 25, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Expands Global Intellectual Property Estate
February 17, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
January 09, 2026
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
December 16, 2025
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
November 06, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
October 27, 2025
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
October 14, 2025
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
October 07, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
October 06, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
September 30, 2025
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
September 24, 2025
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
September 11, 2025
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
September 09, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
September 05, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
September 03, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
August 27, 2025
Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
